bexobrutideg

News

Roche is paying $700m upfront for rights to bexobrutideg, a BTK degrader that it says has potential across oncology, immunology, and neurology.

News

Flagship Pioneering has formed a new AI-focused biotech company, called Etcelera, by combining the platforms of three firms from its portfolio.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.